Relevant and even prescient commentary on news, politics and the economy.

Covid Vaccine Tracker

In a  recent conversation with one person who I would consider knowledgeable, I was led to this site. COVID-19 Live Vaccine Tracker. This is an initial rundown of various Covid vaccines being worked on by international companies and the phase they are in today. I will attempt to update this from time to time.

“A compilation of the active vaccine candidates being studied for coronavirus 2019 (COVID-19) cures. This tracker will update periodically and will have the latest news and information.” The COVID-19 Live Vaccine Tracker, ContagionLive

Phase 3

Vaccine Name: mRNA-1273
Company: Moderna
Moderna’s phase 1 trial, mRNA-1273 vaccine: Results of treating novel coronavirus (COVID-19) were published July 14, 2020 in The New England Journal of Medicine. The NEJM reported on the results of potential vaccine induced protective responses in 45 adult participants receiving doses of 25, 100, or 250 μg (micrograms) throughout March and April 2020.  Antibodies did occur and correlated with higher doses of the mRNA-1273 vaccine as by anti–S-2P antibody GMT (geometric mean titer) ; 40,227 in the 25-μg group, 109,209 in the 100-μg group, and 213,526 in the 250-μg group.

With the second vaccination on day 57, the titers  had again showed increased antibody GMT when tested; 299,751, 782,719, and 1,192,154 μg. Serum-neutralizing activity (antibody that defends a cell from a pathogen or infectious particle by neutralizing any effect it has biologically) was detected by two methods in all participants evaluated, with values generally similar to those in the upper half of the distribution of a panel of control convalescent serum (blood serum containing antibodies  from disease or inoculation) specimens.

Adverse effects, includes half of the participants were fatigued, exhibiting chills, headache, myalgia, with pain at the injection site. Systemic adverse effects occurred after the second vaccination  particularly with the highest dosage. Three participants (21%) in the 250-μg dose group reported one or more severe adverse events.

The mRNA-1273 vaccine had induced anti–SARS-CoV-2 impact with an immune response in all participants of varying intensity with no trial-limiting safety concerns were identified.

mRNA-1273 vaccine was given a  Fast Track designation enrollment for a phase 2 trial at the end of May with an enrollment of 600 in 2 cohorts of those aged 18-55 years and those over 55 years.

A phase 3 trial involving 30,000 volunteers is receiving funding from BARDA and Operation Warp Speed. Participants in the study will receive either an injection of 100 μg mRA-1273 on Days 1 and 29 or a placebo.


Vaccine Name: Inactivated Vaccine
Company: Wuhan Institute of Biological Products; China National Pharmaceutical Group (Sinopharm)

The project involving Sinopharm and the Wuhan Institute of Virology are funded by the China Ministry of Science and Technology to achieve a goal of developing a vaccine utilizing inactivated vaccine. Phase 1 and 2 clinical trials with individuals of ages 6 and up are underway. As of June 16th, 1,120 volunteers participated in the phase 1 and 2 trials. The volunteers have received two injections of the vaccine at low, middle, or high dosing strengths or a placebo scheduled 14 days, 21 days or 28 days apart as reported by China National Biotec Group (CNBG). The seroconversion rate (time period during which a specific antibody develops and becomes detectable in the blood) for the 14-day and 21-day schedule of the mid-dose was 97.6%. At 28 days, it was 100%.

The Inactivate Vaccine appears to be working best at the middle strength when given 28 days apart. All participants in middle strength dosing regime developed neutralizing antibodies.

Sinopharm has initiated a phase 3 trial to evaluate their vaccine candidate in the United Arab Emirates. The country has authorized up to 15,000 participants aged 18 to 60 years to enroll.

China’s Sinopharm touts 100% antibody response for COVID-19 vaccine with workers

Tags: , Comments (4) | |